PowerUp Acquisition Corp ( (PWUP) ) has provided an announcement.
On February 20, 2025, Aspire Biopharma Holdings, Inc. completed its business combination with PowerUp Acquisition Corp, resulting in its public listing on Nasdaq under the ticker symbol ‘ASBP’. The transaction, which garnered approximately $3.8 million, is expected to enhance Aspire’s access to capital, facilitate the expansion of its product development pipeline, and accelerate the commercialization of its innovative fast-absorbing aspirin, which is aimed at cardiology emergencies and pain management. With an emphasis on sustainability, the company aims to advance multiple clinical candidates through regulatory pathways, boosting its industry positioning and potentially offering significant value to stakeholders.
More about PowerUp Acquisition Corp
Aspire Biopharma, Inc., founded in 2021 and headquartered in Humacao, Puerto Rico, is an early-stage biopharmaceutical company focused on developing a novel sublingual delivery mechanism for FDA-approved drugs, nutraceuticals, and supplements. The company is dedicated to improving drug efficacy, dosage management, and rapid absorption, with key products including a fast-acting aspirin formulation for cardiology emergencies, a Viagra/Cialis combination, and various bi-hormonal and supplement products.
YTD Price Performance: -19.09%
Average Trading Volume: 5,691
Technical Sentiment Consensus Rating: Strong Buy
For an in-depth examination of PWUP stock, go to TipRanks’ Stock Analysis page.